The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets
Open accessAbstract
Background: Collectively, research on the role of B-cells in the pathogenesis of multiple sclerosis (MS) illustrates how translational medicine has given rise to promising therapeutic approaches for one of the most debilitating chronic neurological diseases in young adults. First described in 1935, the experimental autoimmune/allergic encephalomyelitis model is a key animal model that has provided the foundation for important developments in targeted therapeutics. Summary: While additional B-cell therapies for MS are presently being developed by the pharmaceutical industry, much remains to be understood about the role played by B-cells in MS. The goal of this review is to summarize how B-cells may contribute to MS pathogenesis and thereby provide a basis for understanding why B-cell depletion is so effective in the treatment of this disease. Key Messages: B-cells are key players in the pathogenesis of MS, and their depletion via B-cell-targeted therapy ameliorates disease activity. Clinical Implications: In 2008, data from the first CD20-targeting B-cell depleting therapeutic trials using rituximab in MS were published. Since then, there has been a large body of evidence demonstrating the effectiveness of B-cell depletion mediated via anti-CD20 antibodies. Intense research efforts focusing on the immunopathological relevance of B-cells has gained significant momentum and given rise to a constellation of promising therapeutic agents for this complex B-cell-driven disease, including novel anti-CD20 antibodies, as well as agents targeting CD19 and BAFF-R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Iwata, Y., Matsushita, T., Horikawa, M., DiLillo, D. J., Yanaba, K., Venturi, G. M., Szabolcs, P. M., Bernstein, S. H., Magro, C. M., Williams, A. D., et al. (2011) · Blood · doi:10.1182/blood-2010-07-294249 · Cited by 1,104
Sex ratio of multiple sclerosis in Canada: a longitudinal study
Orton, S.-M., Herrera, B. M., Yee, I. M., Valdar, W., Ramagopalan, S. V., Sadovnick, A. D., & Ebers, G. C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70581-6 · Cited by 921
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36030 · Cited by 913
Cited by
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
Alizadeh, A., Dyck, S. M., & Karimi-Abdolrezaee, S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00282 · Cited by 1,407
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
Lucchinetti, C. F. (2002) · Brain · doi:10.1093/brain/awf151 · Cited by 1,210
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Autoimmune T cell responses in the central nervous system
Goverman, J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2550 · Cited by 1,030
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Oligodendrocytes: biology and pathology
Bradl, M., & Lassmann, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0601-5 · Cited by 933
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
International MS Genetics Consortium, De Jager, P. L., Jia, X., Wang, J., de Bakker, P. I. W., Ottoboni, L., Aggarwal, N. T., Piccio, L., Raychaudhuri, S., Tran, D., et al. (2009) · Nature Genetics · doi:10.1038/ng.401 · Cited by 800
CNS immune privilege: hiding in plain sight
Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., & Ploix, C. C. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00441.x · Cited by 795
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis
Huseby, E. S., Liggitt, D., Brabb, T., Schnabel, B., Öhlén, C., & Goverman, J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.669 · Cited by 659
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O’Connor, R. A., Anderton, S. M., Bar-Or, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111675 · Cited by 649
Regenerating CNS myelin — from mechanisms to experimental medicines
Franklin, R. J. M., & ffrench-Constant, C. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.136 · Cited by 647
B cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611
Defining the Role of the MHC in Autoimmunity: A Review and Pooled Analysis
Fernando, M. M. A., Stevens, C. R., Walsh, E. C., De Jager, P. L., Goyette, P., Plenge, R. M., Vyse, T. J., & Rioux, J. D. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000024 · Cited by 604
Rosser, E. C., Piper, C. J. M., Matei, D. E., Blair, P. A., Rendeiro, A. F., Orford, M., Alber, D. G., Krausgruber, T., Catalan, D., Klein, N., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.003 · Cited by 579
Kivisäkk, P., Mahad, D. J., Callahan, M. K., Trebst, C., Tucky, B., Wei, T., Wu, L., Baekkevold, E. S., Lassmann, H., Staugaitis, S. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1433000100 · Cited by 549
Machado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 524
Antibody-independent functions of B cells: a focus on cytokines
Shen, P., & Fillatreau, S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3857 · Cited by 508
Herland, A., van der Meer, A. D., FitzGerald, E. A., Park, T.-E., Sleeboom, J. J. F., & Ingber, D. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150360 · Cited by 476
CNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Neurological Diseases in Relation to the Blood–Brain Barrier
Rosenberg, G. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.197 · Cited by 445
Zuccarino-Catania, G. V., Sadanand, S., Weisel, F. J., Tomayko, M. M., Meng, H., Kleinstein, S. H., Good-Jacobson, K. L., & Shlomchik, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2914 · Cited by 444
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Development, Damage, and Repair
Domingues, H. S., Portugal, C. C., Socodato, R., & Relvas, J. B. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00071 · Cited by 432
Human regulatory B cells in health and disease: therapeutic potential
Mauri, C., & Menon, M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci85113 · Cited by 418
Transcriptional analysis of the B cell germinal center reaction
Klein, U., Tu, Y., Stolovitzky, G. A., Keller, J. L., Haddad, J., Miljkovic, V., Cattoretti, G., Califano, A., & Dalla-Favera, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437996100 · Cited by 409
IL-10: A Multifunctional Cytokine in Viral Infections
Rojas, J. M., Avia, M., Martín, V., & Sevilla, N. (2017) · Journal of Immunology Research · doi:10.1155/2017/6104054 · Cited by 408
Mitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Haider, L., Zrzavy, T., Hametner, S., Höftberger, R., Bagnato, F., Grabner, G., Trattnig, S., Pfeifenbring, S., Brück, W., & Lassmann, H. (2016) · Brain · doi:10.1093/brain/awv398 · Cited by 400
Neurofascin as a novel target for autoantibody-mediated axonal injury
Mathey, E. K., Derfuss, T., Storch, M. K., Williams, K. R., Hales, K., Woolley, D. R., Al-Hayani, A., Davies, S. N., Rasband, M. N., Olsson, T., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071053 · Cited by 390
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis
Campbell, G. R., Ziabreva, I., Reeve, A. K., Krishnan, K. J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D. M., & Mahad, D. J. (2011) · Annals of Neurology · doi:10.1002/ana.22109 · Cited by 386
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
Gudi, V., Gingele, S., Skripuletz, T., & Stangel, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00073 · Cited by 430
Animal models of Multiple Sclerosis
Procaccini, C., De Rosa, V., Pucino, V., Formisano, L., & Matarese, G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.042 · Cited by 366
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Love, S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.031195 · Cited by 359
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
Sankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
Patsopoulos, N. A., the Bayer Pharma MS Genetics Working Group, T. S. C. O. S. E. I. A. A. C., & de Bakker, P. I. W. (2011) · Annals of Neurology · doi:10.1002/ana.22609 · Cited by 353
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W.-J., Chen, W.-W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 351
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?
Heesen, C. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065805 · Cited by 345
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Self-citationPersistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
Tsutsui, S., Schnermann, J., Noorbakhsh, F., Henry, S., Yong, V. W., Winston, B. W., Warren, K., & Power, C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4271-03.2004 · Cited by 323
Oxidative stress in multiple sclerosis: Central and peripheral mode of action
Ohl, K., Tenbrock, K., & Kipp, M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.010 · Cited by 317
Brück, W. (2005) · Journal of Neurology · doi:10.1007/s00415-005-5002-7 · Cited by 300
The expanding family of regulatory B cells
Mauri, C., & Menon, M. (2015) · International Immunology · doi:10.1093/intimm/dxv038 · Cited by 297
Transcriptional regulation of memory B cell differentiation
Laidlaw, B. J., & Cyster, J. G. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00446-2 · Cited by 296
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Marik, C., Felts, P. A., Bauer, J., Lassmann, H., & Smith, K. J. (2007) · Brain · doi:10.1093/brain/awm236 · Cited by 292
Epigenetic principles and mechanisms underlying nervous system functions in health and disease
MEHLER, M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.10.001 · Cited by 291
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Neuroprotection and repair in multiple sclerosis
Franklin, R. J. M., ffrench-Constant, C., Edgar, J. M., & Smith, K. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.200 · Cited by 278
Zamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276
Self-citationMeng, X., Grötsch, B., Luo, Y., Knaup, K. X., Wiesener, M. S., Chen, X.-X., Jantsch, J., Fillatreau, S., Schett, G., & Bozec, A. (2018) · Nature Communications · doi:10.1038/s41467-017-02683-x · Cited by 274
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
The role of antigen presenting cells in multiple sclerosis
Chastain, E. M. L., Duncan, D. S., Rodgers, J. M., & Miller, S. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.008 · Cited by 266
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
New markers for murine memory B cells that define mutated and unmutated subsets
Anderson, S. M., Tomayko, M. M., Ahuja, A., Haberman, A. M., & Shlomchik, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062571 · Cited by 261
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Villar, L. M., Sádaba, M. C., Roldán, E., Masjuan, J., González-Porqué, P., Villarrubia, N., Espiño, M., García-Trujillo, J. A., Bootello, A., & Álvarez-Cermeño, J. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522833 · Cited by 259
USP18 lack in microglia causes destructive interferonopathy of the mouse brain
Goldmann, T., Zeller, N., Raasch, J., Kierdorf, K., Frenzel, K., Ketscher, L., Basters, A., Staszewski, O., Brendecke, S. M., Spiess, A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490791 · Cited by 223
Wisnieff, C., Ramanan, S., Olesik, J., Gauthier, S., Wang, Y., & Pitt, D. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25420 · Cited by 245
Trebst, C., Lykke Sørensen, T., Kivisäkk, P., Cathcart, M. K., Hesselgesser, J., Horuk, R., Sellebjerg, F., Lassmann, H., & Ransohoff, R. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63017-9 · Cited by 242
Design and Validation of Diffusion MRI Models of White Matter
Jelescu, I. O., & Budde, M. D. (2017) · Frontiers in Physics · doi:10.3389/fphy.2017.00061 · Cited by 240
Zirngibl, M., Assinck, P., Sizov, A., Caprariello, A. V., & Plemel, J. R. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00538-8 · Cited by 270
Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function
Spiteri, A. G., Wishart, C. L., Pamphlett, R., Locatelli, G., & King, N. J. C. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02384-2 · Cited by 244
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192
Leonard, W. J., & Wan, C.-K. (2016) · F1000Research · doi:10.12688/f1000research.7634.1 · Cited by 184
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Human RNA “Rumor” Viruses: the Search for Novel Human Retroviruses in Chronic Disease
Voisset, C., Weiss, R. A., & Griffiths, D. J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00033-07 · Cited by 157
Maseda, D., Candando, K. M., Smith, S. H., Kalampokis, I., Weaver, C. T., Plevy, S. E., Poe, J. C., & Tedder, T. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300649 · Cited by 144
Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
Kratz, A. L., Murphy, S. L., & Braley, T. J. (2017) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2017.07.002 · Cited by 109
Genetic Association and Altered Gene Expression of Mir-155 in Multiple Sclerosis Patients
Paraboschi, E. M., Soldà, G., Gemmati, D., Orioli, E., Zeri, G., Benedetti, M. D., Salviati, A., Barizzone, N., Leone, M., Duga, S., et al. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12128695 · Cited by 102
Halliday, N., Williams, C., Kennedy, A., Waters, E., Pesenacker, A. M., Soskic, B., Hinze, C., Hou, T. Z., Rowshanravan, B., Janman, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600000 · Cited by 95
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93
Self-citationNeurodegeneration Triggers Peripheral Immune Cell Recruitment into the Forebrain
Scheld, M., Rüther, B. J., Große-Veldmann, R., Ohl, K., Tenbrock, K., Dreymüller, D., Fallier-Becker, P., Zendedel, A., Beyer, C., Clarner, T., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2456-15.2016 · Cited by 82
Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model
Tagge, I., O’Connor, A., Chaudhary, P., Pollaro, J., Berlow, Y., Chalupsky, M., Bourdette, D., Woltjer, R., Johnson, M., & Rooney, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152480 · Cited by 81
IL-17-Induced Act1-Mediated Signaling Is Critical for Cuprizone-Induced Demyelination
Kang, Z., Liu, L., Spangler, R., Spear, C., Wang, C., Gulen, M. F., Veenstra, M., Ouyang, W., Ransohoff, R. M., & Li, X. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0841-12.2012 · Cited by 78
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76
Zeis, T., Probst, A., Steck, A. J., Stadelmann, C., Brück, W., & Schaeren‐Wiemers, N. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00231.x · Cited by 76
Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions
Lerma-Martin, C., Badia-i-Mompel, P., Ramirez Flores, R. O., Sekol, P., Schäfer, P. S. L., Riedl, C. J., Hofmann, A., Thäwel, T., Wünnemann, F., Ibarra-Arellano, M. A., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01796-z · Cited by 76
Kallaur, A. P., Oliveira, S. R., Simão, A. N. C., Alfieri, D. F., Flauzino, T., Lopes, J., de Carvalho Jennings Pereira, W. L., de Meleck Proença, C., Borelli, S. D., Kaimen-Maciel, D. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9846-x · Cited by 75
Böttcher, C., van der Poel, M., Fernández-Zapata, C., Schlickeiser, S., Leman, J. K. H., Hsiao, C.-C., Mizee, M. R., Adelia, Vincenten, M. C. J., Kunkel, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01010-8 · Cited by 58
Metadata
- Authors
- von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 73
- Issue
- 3-4
- Pages
- 238-246
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2086080135
- Cited by
- 1,463
- References
- 78
- FWCI
- 113.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.